{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:55:33Z","timestamp":1764996933139},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T00:00:00Z","timestamp":1331251200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s12072-012-9355-6","type":"journal-article","created":{"date-parts":[[2012,3,8]],"date-time":"2012-03-08T18:28:27Z","timestamp":1331231307000},"page":"684-695","source":"Crossref","is-referenced-by-count":20,"title":["Natural history of HCV infection"],"prefix":"10.1007","volume":"6","author":[{"given":"Shiv K.","family":"Sarin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,9]]},"reference":[{"issue":"10","key":"9355_CR1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","volume":"194","author":"R Thimme","year":"2001","unstructured":"Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194(10):1395\u20131406","journal-title":"J Exp Med"},{"issue":"5","key":"9355_CR2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2036.2010.04549.x","volume":"33","author":"R Loomba","year":"2011","unstructured":"Loomba R, Rivera MM, McBurney R, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011;33(5):559\u2013565","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"9355_CR3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-115-2-111","volume":"115","author":"TL Wright","year":"1991","unstructured":"Wright TL, Hsu H, Donegan E, et al. Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med 1991;115(2):111\u2013112","journal-title":"Ann Intern Med"},{"issue":"56","key":"9355_CR4","first-page":"556","volume":"51","author":"T Kanda","year":"2004","unstructured":"Kanda T, Yokosuka O, Imazeki F, et al. Acute hepatitis C virus infection, 1986\u20132001: a rare cause of fulminant hepatitis in Chiba, Japan. Hepatogastroenterology 2004;51(56):556\u2013558","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"9355_CR5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1017\/S0950268806006388","volume":"135","author":"J Amin","year":"2007","unstructured":"Amin J, Law MG, Micallef J, et al. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect 2007;135(1):144\u2013150","journal-title":"Epidemiol Infect"},{"issue":"4","key":"9355_CR6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0168-8278(01)00151-9","volume":"35","author":"S Bellentani","year":"2001","unstructured":"Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001;35(4):531\u2013537","journal-title":"J Hepatol"},{"key":"9355_CR7","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1099\/vir.0.033910-0","volume":"92","author":"EC Thomson","year":"2011","unstructured":"Thomson EC, Smith JA, Klenerman P. The natural history of early hepatitis C virus evolution; lessons from a global outbreak in HIV-1 infected individuals. J Gen Virol 2011;92:2227\u20132236","journal-title":"J Gen Virol"},{"issue":"4","key":"9355_CR8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","volume":"284","author":"DL Thomas","year":"2000","unstructured":"Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284(4):450\u2013456","journal-title":"JAMA"},{"key":"9355_CR9","doi-asserted-by":"crossref","first-page":"13779","DOI":"10.1128\/JVI.78.24.13779-13792.2004","volume":"78","author":"CB Bigger","year":"2004","unstructured":"Bigger CB, Guerra B, Brasky KM, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78:13779\u201313792","journal-title":"J Virol"},{"key":"9355_CR10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cytogfr.2007.06.006","volume":"18","author":"BC Keller","year":"2007","unstructured":"Keller BC, Johnson CL, Erickson AK, et al. Innate immune evasion by hepatitis C virus and West Nile virus. Cytokine Growth Factor Rev 2007;18:535\u2013544","journal-title":"Cytokine Growth Factor Rev"},{"key":"9355_CR11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00018-008-8270-4","volume":"66","author":"J Post","year":"2009","unstructured":"Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009;66:733\u2013756","journal-title":"Cell Mol Life Sci"},{"key":"9355_CR12","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1084\/jem.20030239","volume":"197","author":"NH Shoukry","year":"2003","unstructured":"Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645\u20131655","journal-title":"J Exp Med"},{"key":"9355_CR13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2010.12.033","volume":"55","author":"M Zeremski","year":"2011","unstructured":"Zeremski M, Hooker G, Shu MA, et al. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol 2011;55:545\u2013552","journal-title":"J Hepatol"},{"issue":"4","key":"9355_CR14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1478-3231.2011.02449.x","volume":"31","author":"M Romero-Gomez","year":"2011","unstructured":"Romero-Gomez M, Eslam M, Ruiz A, et al. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int 2011;31(4):443\u2013460","journal-title":"Liver Int"},{"issue":"7265","key":"9355_CR15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461(7265):798\u2013801","journal-title":"Nature"},{"issue":"6","key":"9355_CR16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1053\/j.gastro.2008.02.069","volume":"134","author":"SB Missiha","year":"2008","unstructured":"Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134(6):1699\u20131714","journal-title":"Gastroenterology"},{"key":"9355_CR17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJM199506013322202","volume":"332","author":"MJ Tong","year":"1995","unstructured":"Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463\u20131466","journal-title":"N Engl J Med"},{"key":"9355_CR18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.1840120409","volume":"12","author":"K Kiyosawa","year":"1990","unstructured":"Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671\u2013675","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"9355_CR19","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","volume":"36","author":"LB Seeff","year":"2002","unstructured":"Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35\u2013S46","journal-title":"Hepatology"},{"key":"9355_CR20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418\u2013431","journal-title":"Hepatology"},{"key":"9355_CR21","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1111\/j.1365-2893.2010.01406.x","volume":"18","author":"A Lawson","year":"2011","unstructured":"Lawson A, Trent Hepatitis C Study Group. A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. J Viral Hepat 2011;18:e270\u2013e277","journal-title":"J Viral Hepat"},{"issue":"3","key":"9355_CR22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2","volume":"75","author":"F Donato","year":"1998","unstructured":"Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75(3):347\u2013354","journal-title":"Int J Cancer"},{"key":"9355_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1386-6346(02)00039-6","volume":"24","author":"K Kiyosawa","year":"2002","unstructured":"Kiyosawa K. Trend of liver cirrhosis as precancerous lesions. Hepatol Res 2002;24:40\u201345","journal-title":"Hepatol Res"},{"issue":"3","key":"9355_CR24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2010.04370.x","volume":"32","author":"W Alazawi","year":"2010","unstructured":"Alazawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010;32(3):344\u2013355","journal-title":"Aliment Pharmacol Ther"},{"key":"9355_CR25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/hep.21826","volume":"46","author":"S Bruno","year":"2007","unstructured":"Bruno S, Crosignani A, Maisonneuve P, et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007;46:1350\u20131356","journal-title":"Hepatology"},{"key":"9355_CR26","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/hep.510280632","volume":"28","author":"C Niederau","year":"1998","unstructured":"Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687\u20131695","journal-title":"Hepatology"},{"key":"9355_CR27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463\u2013472","journal-title":"Gastroenterology"},{"key":"9355_CR28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cgh.2010.09.014","volume":"9","author":"LH Omland","year":"2011","unstructured":"Omland LH, Jepsen P, Krarup H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol 2011;9:71\u201378","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9355_CR29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(06)69374-4","volume":"368","author":"J Amin","year":"2006","unstructured":"Amin J, Law MG, Bartlett M, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368:938\u2013945","journal-title":"Lancet"},{"issue":"4","key":"9355_CR30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1440-1746.2008.05649.x","volume":"24","author":"SS Hissar","year":"2009","unstructured":"Hissar SS, Kumar M, Tyagi P, et al. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India. J Gastroenterol Hepatol 2009;24(4):581\u2013587","journal-title":"J Gastroenterol Hepatol"},{"key":"9355_CR31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.1140485","volume":"317","author":"WE Naugler","year":"2007","unstructured":"Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121\u2013124","journal-title":"Science"},{"key":"9355_CR32","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","volume":"34","author":"T Poynard","year":"2001","unstructured":"Poynard T, Ratziu V, Charlotte F, et al. Rate and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730\u2013739","journal-title":"J Hepatol"},{"key":"9355_CR33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.21580","volume":"45","author":"GC Nguyen","year":"2007","unstructured":"Nguyen GC, Segev DL, Thuluvath PJ. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology 2007;45:1282\u20131289","journal-title":"Hepatology"},{"key":"9355_CR34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1086\/500938","volume":"42","author":"JD Scott","year":"2006","unstructured":"Scott JD, McMahon BJ, Bruden D, et al. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. Clin Infect Dis 2006;42:945\u2013952","journal-title":"Clin Infect Dis"},{"key":"9355_CR35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jmv.20562","volume":"78","author":"M Kobayashi","year":"2006","unstructured":"Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child\u2013Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006;78:459\u2013465","journal-title":"J Med Virol"},{"key":"9355_CR36","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1053\/j.gastro.2005.09.010","volume":"129","author":"T Asselah","year":"2005","unstructured":"Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005;129:2064\u20132075","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"9355_CR37","first-page":"438A","volume":"52","author":"D Bitetto","year":"2010","unstructured":"Bitetto D, Fabris C, Fornasiere E, et al. IL28B rs12979860 C\u00a0>\u00a0T polymorphism affects the evolution of chronic Hepatitis C. Hepatology 2010;52(Suppl):438A","journal-title":"Hepatology"},{"issue":"Suppl","key":"9355_CR38","first-page":"748A","volume":"52","author":"JA Campo Del","year":"2010","unstructured":"Del Campo JA, Maraver Zamora M, Ramirez-Lorca R, et al. Real LM.IL28B polymorphism predicts sustained virological response in hepatitis C but is not associated with fibrosis or viral load. Hepatology 2010;52(Suppl):748A","journal-title":"Hepatology"},{"key":"9355_CR39","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/hep.23826","volume":"52","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Clark PJ, Fellay J, et al. IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the ideal study. Hepatology 2010;52:2243\u20132244","journal-title":"Hepatology"},{"issue":"4","key":"9355_CR40","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.24503","volume":"54","author":"F Marabita","year":"2011","unstructured":"Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011;54(4):1127\u20131134","journal-title":"Hepatology"},{"key":"9355_CR41","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2006.02.032","volume":"130","author":"H Huang","year":"2006","unstructured":"Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006;130:1679\u20131687","journal-title":"Gastroenterology"},{"key":"9355_CR42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-134-2-200101160-00012","volume":"134","author":"DR Harris","year":"2001","unstructured":"Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120\u2013124","journal-title":"Ann Intern Med"},{"key":"9355_CR43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2007.10.021","volume":"6","author":"JH Ishida","year":"2008","unstructured":"Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008;6:69\u201375","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9355_CR44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","volume":"33","author":"CS Graham","year":"2001","unstructured":"Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562\u2013569","journal-title":"Clin Infect Dis"},{"key":"9355_CR45","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/hep.23162","volume":"50","author":"ND Freedman","year":"2009","unstructured":"Freedman ND, Everhart JE, Lindsay KL, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009;50:1360\u20131369","journal-title":"Hepatology"},{"key":"9355_CR46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.23279","volume":"51","author":"AA Modi","year":"2010","unstructured":"Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010;51:201\u2013209","journal-title":"Hepatology"},{"key":"9355_CR47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/j.gastro.2009.05.007","volume":"137","author":"JE Everhart","year":"2009","unstructured":"Everhart JE, Lok AS, Kim HY, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009;137:549\u2013557","journal-title":"Gastroenterology"},{"key":"9355_CR48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/hep.510230403","volume":"23","author":"M Kobayashi","year":"1996","unstructured":"Kobayashi M, Tanaka E, Sodayama T, et al. The natural course of chronic hepatitis C: a comparison between patients with genotype 1 and 2 hepatitis C viruses. Hepatology 1996;23:669\u2013695","journal-title":"Hepatology"},{"key":"9355_CR49","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.510250344","volume":"25","author":"S Bruno","year":"1997","unstructured":"Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754\u2013758","journal-title":"Hepatology"},{"key":"9355_CR50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/gut.2003.018770","volume":"53","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004;53:406\u2013412","journal-title":"Gut"},{"key":"9355_CR51","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","volume":"51","author":"PY Bochud","year":"2009","unstructured":"Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655\u2013666","journal-title":"J Hepatol"},{"key":"9355_CR52","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jhep.2009.08.001","volume":"51","author":"S Nicola De","year":"2009","unstructured":"De Nicola S, Aghemo A, Rumi MG, et al. HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:964\u2013966","journal-title":"J Hepatol"},{"key":"9355_CR53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/hep.510250138","volume":"25","author":"L Benvegnu","year":"1997","unstructured":"Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25:211\u2013215","journal-title":"Hepatology"},{"key":"9355_CR54","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0168-8278(01)00055-1","volume":"34","author":"T Poynard","year":"2001","unstructured":"Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:764\u2013767","journal-title":"J Hepatol"},{"key":"9355_CR55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2893.2006.00795.x","volume":"14","author":"HE Harris","year":"2007","unstructured":"Harris HE, Eldridge KP, Harbour S, et al. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepatol 2007;14:213\u2013220","journal-title":"J Viral Hepat"},{"key":"9355_CR56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-122-3-199502010-00001","volume":"122","author":"JB Nousbaum","year":"1995","unstructured":"Nousbaum JB, Pol S, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 1995;122:161\u2013168","journal-title":"Ann Intern Med"},{"key":"9355_CR57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1097-0215(19960927)68:1<51::AID-IJC10>3.0.CO;2-9","volume":"68","author":"A Hatzakis","year":"1996","unstructured":"Hatzakis A, Katsoulidou A, Kaklamani E, et al. Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: a case-control study. Int J Cancer 1996;68:51\u201353","journal-title":"Int J Cancer"},{"key":"9355_CR58","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/hep.510250340","volume":"25","author":"S Mihm","year":"1997","unstructured":"Mihm S, Fayyazi A, Hartmann H, et al. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997;25:735\u2013739","journal-title":"Hepatology"},{"key":"9355_CR59","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/hep.22127","volume":"47","author":"S Kamal","year":"2008","unstructured":"Kamal S, Nasser I. Hepatitis C genotype 4: what we know and what we don\u2019t yet know. Hepatology 2008;47:1371\u20131383","journal-title":"Hepatology"},{"key":"9355_CR60","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1478-3231.2009.02188.x","volume":"30","author":"N Antaki","year":"2010","unstructured":"Antaki N, Craxi A, Kamal SM, et al. The neglected hepatitis C virus genotype 4, 5 and 6: an international consensus report. Liver Int 2010;30:342\u2013355","journal-title":"Liver Int"},{"key":"9355_CR61","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/hep.21117","volume":"43","author":"SM Kamal","year":"2006","unstructured":"Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum marker of fibrosis. Hepatology 2006;43:771\u2013779","journal-title":"Hepatology"},{"issue":"3","key":"9355_CR62","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jhep.2010.04.009","volume":"53","author":"WK Seto","year":"2010","unstructured":"Seto WK, Lai CL, Fung J, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010;53(3):444\u2013448","journal-title":"J Hepatol"},{"key":"9355_CR63","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.510230607","volume":"23","author":"M Yano","year":"1996","unstructured":"Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334\u20131337","journal-title":"Hepatology"},{"key":"9355_CR64","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1053\/j.gastro.2011.01.053","volume":"140","author":"RW Lambrecht","year":"2011","unstructured":"Lambrecht RW, Sterling RK, Naishadham D, et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011;140:1490\u20131500","journal-title":"Gastroenterology"},{"key":"9355_CR65","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/jhep.2001.22346","volume":"33","author":"AM Bisceglie Di","year":"2001","unstructured":"Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, et al. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001;33:704\u2013707","journal-title":"Hepatology"},{"key":"9355_CR66","doi-asserted-by":"crossref","first-page":"330","DOI":"10.7326\/0003-4819-123-5-199509010-00002","volume":"123","author":"AO Shakil","year":"1995","unstructured":"Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330\u2013337","journal-title":"Ann Intern Med"},{"key":"9355_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-9071(199601)48:1<1::AID-JMV1>3.0.CO;2-E","volume":"48","author":"N Kuzushita","year":"1996","unstructured":"Kuzushita N, Hayashi N, Katayama K, et al. Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J Med Virol 1996;48:1\u20137","journal-title":"J Med Virol"},{"key":"9355_CR68","first-page":"285","volume":"21","author":"E Silini","year":"1995","unstructured":"Silini E, Bono F, Cividini A, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285\u2013290","journal-title":"Hepatology"},{"key":"9355_CR69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/gast.1996.v110.pm8536854","volume":"110","author":"D Prati","year":"1996","unstructured":"Prati D, Capelli C, Zanella A, et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 1996;110:178\u2013183","journal-title":"Gastroenterology"},{"key":"9355_CR70","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-137-12-200212170-00009","volume":"137","author":"A Alberti","year":"2002","unstructured":"Alberti A, Noventa F, Benvegn\u00f9 L, et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002;137:961\u2013964","journal-title":"Ann Intern Med"},{"key":"9355_CR71","first-page":"418","volume":"22","author":"M Shindo","year":"1995","unstructured":"Shindo M, Arai K, Sokawa Y, et al. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995;22:418\u2013425","journal-title":"Hepatology"},{"key":"9355_CR72","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cgh.2006.02.002","volume":"4","author":"ML Shiffman","year":"2006","unstructured":"Shiffman ML, Diago M, Tran A, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006;4:645\u2013652","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"9355_CR73","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<688::AID-CNCR5>3.0.CO;2-A","volume":"79","author":"K Tarao","year":"1997","unstructured":"Tarao K, Takemiya S, Tamai S, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79(4):688\u2013694","journal-title":"Cancer"},{"key":"9355_CR74","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.gastro.2009.09.007","volume":"138","author":"MG Ghany","year":"2010","unstructured":"Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136\u2013146","journal-title":"Gastroenterology"},{"key":"9355_CR75","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/j.1572-0241.1999.01151.x","volume":"94","author":"PA Bonis","year":"1999","unstructured":"Bonis PA, Tong MJ, Blatt LM, et al. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol 1999;94:1605\u20131612","journal-title":"Am J Gastroenterol"},{"key":"9355_CR76","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.510310236","volume":"31","author":"MH Khan","year":"2000","unstructured":"Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000;31:513\u2013520","journal-title":"Hepatology"},{"issue":"7","key":"9355_CR77","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","volume":"132","author":"Y Shiratori","year":"2000","unstructured":"Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132(7):517\u2013524","journal-title":"Ann Intern Med"},{"issue":"2","key":"9355_CR78","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/gast.2002.34785","volume":"123","author":"H Yoshida","year":"2002","unstructured":"Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123(2):483\u2013491","journal-title":"Gastroenterology"},{"issue":"3","key":"9355_CR79","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.2003.030353","volume":"53","author":"H Yoshida","year":"2004","unstructured":"Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004;53(3):425\u2013430","journal-title":"Gut"},{"issue":"2","key":"9355_CR80","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.20073","volume":"39","author":"C Camm`a","year":"2004","unstructured":"Camm`a C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004;39(2):333\u2013342","journal-title":"Hepatology"},{"issue":"7","key":"9355_CR81","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2036.2008.03620.x","volume":"27","author":"GT Everson","year":"2008","unstructured":"Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Alimentary Pharmacol Ther 2008;27(7):542\u2013551","journal-title":"Alimentary Pharmacol Ther"},{"key":"9355_CR82","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1386-6346(02)00016-5","volume":"23","author":"T Okanoue","year":"2002","unstructured":"Okanoue T, Itoh Y, Kirishima T, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res 2002;23:62\u201377","journal-title":"Hepatol Res"},{"issue":"3","key":"9355_CR83","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131(3):174\u2013181","journal-title":"Ann Intern Med"},{"issue":"2","key":"9355_CR84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","volume":"142","author":"Y Shiratori","year":"2005","unstructured":"Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142(2):105\u2013114","journal-title":"Ann Intern Med"},{"issue":"5","key":"9355_CR85","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52(5):652\u2013657","journal-title":"J Hepatol"},{"issue":"2","key":"9355_CR86","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cgh.2009.10.026","volume":"8","author":"AK Singal","year":"2010","unstructured":"Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010;8(2):192\u2013199","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"9355_CR87","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","volume":"51","author":"S Bruno","year":"2010","unstructured":"Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child\u2013Pugh class A hepatitis C virus induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51(6):2069\u20132076","journal-title":"Hepatology"},{"issue":"2","key":"9355_CR88","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1046\/j.1365-2893.2003.00481.x","volume":"11","author":"A Kasahara","year":"2004","unstructured":"Kasahara A, Tanaka H, Okanoue T, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepatol 2004;11(2):148\u2013156","journal-title":"J Viral Hepat"},{"issue":"2","key":"9355_CR89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jhep.2008.04.012","volume":"49","author":"S Deuffic-Burban","year":"2008","unstructured":"Deuffic-Burban S, Deltenre P, Louvet A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 2008;49(2):175\u2013183","journal-title":"J Hepatol"},{"key":"9355_CR90","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/gut.52.4.574","volume":"52","author":"M Wright","year":"2003","unstructured":"Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross-sectional and longitudinal study. Gut 2003;52:574\u2013579","journal-title":"Gut"},{"key":"9355_CR91","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2004.06.052","volume":"127","author":"WR Kim","year":"2004","unstructured":"Kim WR, Poterucha JJ, Benson JT, et al. The impact of competing risks on the observed rate of chronic hepatitis C progression. Gastroenterology 2004;127:749\u2013755","journal-title":"Gastroenterology"},{"key":"9355_CR92","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.gastro.2004.12.018","volume":"128","author":"T Poynard","year":"2005","unstructured":"Poynard T, Ratziu V, Kim N, et al. Age and gender will survive to competing risks as fibrosis factors. Gastroenterology 2005;128:519\u2013520","journal-title":"Gastroenterology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-012-9355-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-012-9355-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-012-9355-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:37:11Z","timestamp":1559446631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-012-9355-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,9]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["9355"],"URL":"https:\/\/doi.org\/10.1007\/s12072-012-9355-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,9]]}}}